(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
about
Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingProstate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617.F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients.Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.Metal-Based PSMA Radioligands.Topics of nuclear medicine research in Europe.[Begin salvage radiotherapy early after diagnosis of PSA recurrence].Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.Comparing nodal versus bony metastatic spread using tumour phylogenies.Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.Current status of theranostics in prostate cancer.(68) Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer.Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review.The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.Patterns of relapse as determined by (68)Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.Advances in prostate-specific membrane antigen PET of prostate cancer.The use of PET/CT in prostate cancer.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.Performance of 68Ga-PSMA PET/CT for Prostate Cancer Management at Initial Staging and Time of Biochemical Recurrence.[PET-CT and PET-MRI of the prostate : From 18F-FDG to 68Ga-PSMA].See the unseen: Mesorectal lymph node metastases in prostate cancer.The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.Can Gallium-68 Prostate-specific Membrane Antigen Ligand be a Potential Radiotracer for Renal Cortical Positron Emission Tomography Imaging?Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression.Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.Clinical implications of PET/CT in prostate cancer management
P2860
Q28074669-A0774F3F-45E3-4222-9EB0-213DE395E69FQ33914844-8DD23A80-770E-40E7-A2F9-B15940E89219Q36999897-D93381DA-7424-4E46-9F99-1D0A64CA40C7Q37594922-94E9092D-D9CB-4E69-8B6B-8446F1A1193DQ37662669-9BD6CA57-94FC-4824-97F3-7733415A2D26Q38613594-2A97B92F-C13B-4199-86F0-18AD1032724AQ38641232-BC00BFC4-D65F-4E36-86C4-8F56584D6FC2Q38720852-13D2760A-E86F-459B-8680-F19FA825E2DDQ38804450-8F6DDA07-A692-4AEA-A2AA-DA07359043D4Q38895102-008B2FDF-D461-4867-83B7-FA6B7DDA6D7FQ38966705-277DE960-F293-4643-B577-8C37AFF08E36Q38982759-978BFF75-BC74-48CC-A79A-9CCD6F743A03Q39198527-2B15B425-775B-4CF6-BAEB-B5F17171E850Q39458746-6B5DA4BA-4AB5-4289-AC8E-01685799D0F5Q40512483-5EB98EED-513B-4378-A37B-85FE4980DBF4Q40913769-5B912987-9A42-44C8-94DC-B3C8CA33711AQ41147905-043A907E-4D17-43ED-B54C-EB606CC295ADQ41336766-34756F64-B55E-4B40-9148-0319485CAC77Q47107456-732D44C3-4EC1-4EAC-9425-E58668E4D7CDQ47241139-4E96839D-85DD-4811-8624-3292B85B9AEBQ47693515-99C9728F-ECEF-48A4-B74A-5542973DED22Q48089415-6E8A01D6-F57C-489B-B05A-7128C2EF476FQ48108274-251D81EB-AA89-46EE-B808-4492FAB14CEBQ48116656-990B7EB9-346B-45DF-9BED-CD404D7B6F48Q48222301-C85A6804-D0AA-47EA-9281-CA9BF72DC8CBQ48262413-5B8B2AEB-49CF-491B-93D1-CDB8ACAB288BQ48311297-0FA94DEF-B92B-485D-A847-FCD0C9E4CA8BQ48316900-E8896F06-7838-4D72-833B-F293C410C975Q49713199-1EE4E1C1-A333-4181-8409-91E438EA0662Q49919217-738E7A27-6511-4A73-96BF-0E914FC1A715Q50083626-BF1D04BE-587F-4FC0-84C4-A9AB33FB0236Q50182743-2A455EEC-87BC-4543-A825-CAEC53E88D9AQ52938281-16A853D4-637C-48EF-B471-0A5F31D2BB47Q53174206-4BF6A444-34C0-4317-9712-90E3F1D101BBQ53578187-D456BD36-24D1-42F7-9E9C-8D9BD5BEAC70Q55005852-D4032BD0-2DB2-4C3E-8A68-ED468D7D7706Q55039909-17BD8771-17AC-4F9B-BC4D-95B69D0AA197Q55118858-4F89F01E-5566-45A5-8F2C-B6873A703764Q55399763-7056BAC1-112C-49F3-8E36-74E99C6D3A23Q59137133-685536C5-2BC2-4A7B-B96D-66A7B3FCAC9B
P2860
(68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@ast
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@en
type
label
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@ast
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@en
prefLabel
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@ast
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@en
P2093
P2860
P1476
(68)Ga-PSMA-11 PET/CT: a new t ...... t of prostate cancer patients.
@en
P2093
Ali Afshar-Oromieh
Clemens Kratochwil
Florian Sterzing
Frederik L Giesel
Gregor Habl
Hannah Fiedler
Klaus Kopka
Sonja Katayama
Uwe Haberkorn
P2860
P2888
P356
10.1007/S00259-015-3188-1
P50
P577
2015-09-25T00:00:00Z